Compare Cenovus Energy Inc (CVE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Sanofi SA — how do they compare? Cenovus Energy Inc trades at $31.39 (market cap $57.90B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Sanofi SA for 94 Days on average.
| CVE | SNY | |
|---|---|---|
Market Cap | $57.90B | $95.18B |
Volume | 7,863,588 | 2,995,646 |
Sector | Energy | Health |
52-Week High | $33.92 | $52.34 |
52-Week Low | $15.85 | $39.51 |
Typical Hold Time | 46 Days | 94 Days |
Enterprise Value | $63.84B | $114.48B |
Dividend Yield | 1.97% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.49, up 2.81% today, with a bullish technical signal and strong fundamental metrics including a P/E of 12.43 and ROE of 20.96%. The company has beaten earnings estimates in three of the last four quarters and maintains solid cash flow generation despite recent net cash outflows. Recent analyst upgrades and positive media coverage highlight growing investor confidence in the energy sector.
CVE presents a compelling value opportunity with attractive valuation ratios and strong profitability metrics. Key risks include commodity price volatility and execution challenges in capital investments. Wall Street sentiment is cautiously optimistic with 40.7% buy ratings, though the majority maintain hold positions awaiting clearer earnings momentum.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
